When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...

Active antisense oligonucleotides directed against the insulin-like growth factor type I receptor (IGF-IR/AS ODN) have shown potential as an antitumour agent in animal studies. In April Journal of ...

Antisense oligonucleotides (ASOs), which bind to RNA and prevent them from being translated into proteins, have gained popularity in recent years as a way to treat neurodegenerative diseases. However, ...

Researchers found that adding a newly developed modified sugar, BNAP-AEO, to gapmer antisense oligonucleotides (ASOs) increased their affinity for target RNAs, thus significantly enhancing their ...

Stargardt disease type 1 (STGD1) is an inherited retinal recessive disease caused by biallelic variants in the ABCA4 gene. One of the recurrent variants is located at the exon-intron junction of exon ...

Researchers from Japan investigated how ASOs administered locally into the brains of mice models for Parkinson’s disease can help prevent the formation and spread of harmful aSyn aggregates through ...

MUNICH, DE / ACCESS Newswire / May 23, 2025 / Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, will present new ...

Please provide your email address to receive an email when new articles are posted on . Wave Life Sciences has announced positive results from its phase 1b/2a clinical trial of WVE-003, a potential ...

AMX0114 is an investigational antisense oligonucleotide targeting calpain-2, a calcium-activated protease believed to play a role in ALS disease progression. The Food and Drug Administration (FDA) has ...